相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Laura Bonanno et al.
BRITISH JOURNAL OF CANCER (2022)
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
Yan Hu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien et al.
LANCET ONCOLOGY (2022)
P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
M. Tsuboi et al.
Journal of Thoracic Oncology (2021)
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
Christos Sachpekidis et al.
EJNMMI RESEARCH (2021)
The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review
Lawek Berzenji et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A. Shu et al.
LANCET ONCOLOGY (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Liwen Xiong et al.
ONCOLOGIST (2019)
Radical surgical resection after neoadjuvant targeted therapy in non-small cell lung cancer: a single-center retrospective study of 6 cases
Zhenyang Zhang et al.
JOURNAL OF THORACIC DISEASE (2019)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement
Chao Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review
Niccolo Giaj-Levra et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
Matthew J. Bott et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors
Matthew J. Bott et al.
ANNALS OF THORACIC SURGERY (2018)
IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer
X. Mignard et al.
REVUE DES MALADIES RESPIRATOIRES (2018)
Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy
Ye Ning et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
Kristen M. Cunanan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape
Hawazin Faruki et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
Martin E. Gutierrez et al.
CLINICAL LUNG CANCER (2017)
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
Francesco Passiglia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lung Cancer in the Era of Precision Medicine
Katerina Politi et al.
CLINICAL CANCER RESEARCH (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Lars Henning Schmidt et al.
PLOS ONE (2015)
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
Sarah Burdett et al.
LANCET (2014)
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
分享论文
